News and Events

Subscribe to our press distribution list to receive the latest news about AMW.

Upcoming

Events

No events available

Past

Events

Archive

Pharmapack

January 24-25, 2024 Paris, France https://www.pharmapackeurope.com/

Pharmasynergy

February 08-09, 2024
London, UK

euroPLX84

February 26-27, 2024 Lisbon, Portugal

BIO-Europe Spring

March 18-20, 2024
Barcelona, Spain
https://informaconnect.com/bioeurope-spring/

4th Wet AMD & Diabetic Eye Disease Drug Development

March 19-21, 2024
Boston, MA
https://wet-amd-drug-development.com/

BIO International Convention

June 03-06, 2024
San Diego, California
https://www.bio.org/events/bio-international-convention

CPHI South East Asia

July 10-12, 2024 Bangkok, Thailand https://www.cphi.com/sea/en/home.html

CPHI 2024

October 08-10, 2024 Milan, Italy https://www.cphi.com/europe/en/home.html

PODD – Partnership Opportunities in Drug Delivery

October 28-29, 2024 Boston, USA https://poddconference.com

BIO-Europe

November 04-06, 2024 Stockholm, Sweden https://informaconnect.com/bioeurope/

Latest

News

11. July 2017

Endomedica GmbH, our wholly owned subsidiary based in Halle, was able to present itself to a wide audience including well-known pharmaceutical companies and investors from the fields of biotechnology and medical technology at the Health Innovation Summit on 11.7.2017.

The event took place simultaneously as a webinar in Munich, Tokyo and Silicon Valley and allowed discussion rounds after the presentation.

22. June 2017

On 22 June 2017, the AMW received a high visit from the Bavarian Minister of Economic Affairs and Deputy Prime Minister of the Free State of Bavaria.

Within this framework, the pharmaceutical plant was able to present itself as the largest training company in Warngau.

9. November 2016

Specialty pharmaceutical company AMW takes big steps

Warngau – AMW GmbH, founded in 2008 and based in Warngau south of Munich, is a dynamically growing specialist pharmaceutical company with bright prospects. The company develops and distributes transdermal systems, i.e. active ingredients that enter the body through the skin, as well as implants loaded with highly effective active ingredients, which release their active ingredient evenly to the body for months and dissolve completely. AMW is supported by well-known investors. In a recent financing round to finance growth, investors reaffirmed their commitment to AMW and contributed a further six million euros.

6. February 2016

Chamber of Commerce Munich and Upper Bavaria: Training company 2016

This company ensures qualitythrough vocational training in several occupations.

4. November 2015

For the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.

The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.

For press and news inquiries please send an e-mail to news@a-m-w.eu